CA2580679A1 - Variants and chemically-modified variants of phenylalanine ammonia-lyase - Google Patents

Variants and chemically-modified variants of phenylalanine ammonia-lyase Download PDF

Info

Publication number
CA2580679A1
CA2580679A1 CA002580679A CA2580679A CA2580679A1 CA 2580679 A1 CA2580679 A1 CA 2580679A1 CA 002580679 A CA002580679 A CA 002580679A CA 2580679 A CA2580679 A CA 2580679A CA 2580679 A1 CA2580679 A1 CA 2580679A1
Authority
CA
Canada
Prior art keywords
pal
protein
peg
activity
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002580679A
Other languages
English (en)
French (fr)
Inventor
Alejandra Gamez
Lin Wang
Woomi Kim
Mary Straub
Marianne G. Patch
Emil Kakkis
Dan Oppenheimer
Paul A. Fitzpatrick
Robert Heft
Raymond C. Stevens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Biomarin Pharmaceutical Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2580679A1 publication Critical patent/CA2580679A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CA002580679A 2004-09-17 2005-09-19 Variants and chemically-modified variants of phenylalanine ammonia-lyase Abandoned CA2580679A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US61077004P 2004-09-17 2004-09-17
US60/610,770 2004-09-17
US65195005P 2005-02-09 2005-02-09
US60/651,950 2005-02-09
PCT/US2005/033895 WO2006034373A2 (en) 2004-09-17 2005-09-19 Variants and chemically-modified variants of phenylalanine ammonia-lyase

Publications (1)

Publication Number Publication Date
CA2580679A1 true CA2580679A1 (en) 2006-03-30

Family

ID=36090659

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002580679A Abandoned CA2580679A1 (en) 2004-09-17 2005-09-19 Variants and chemically-modified variants of phenylalanine ammonia-lyase

Country Status (6)

Country Link
US (1) US7553653B2 (https=)
EP (1) EP1814984A2 (https=)
JP (1) JP2008513027A (https=)
AU (1) AU2005286763A1 (https=)
CA (1) CA2580679A1 (https=)
WO (1) WO2006034373A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1708690T3 (pl) 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
ES2409756T3 (es) * 2006-12-04 2013-06-27 Promedior, Inc. Combinación de SAP y de enalapril para su uso en tratamiento de trastornos fibróticos o fibroproliferativos
LT2545939T (lt) 2007-04-11 2021-03-10 Biomarin Pharmaceutical Inc. Tetrahidrobiopterinas, skirtas gydyti ligas, susijusias supadidėjusiu fenilalanino kiekiu
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US7560263B2 (en) * 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2010014225A2 (en) * 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
CA2754961C (en) * 2009-03-11 2018-04-10 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
EP2405929B1 (en) * 2009-03-11 2018-06-06 Promedior Inc. A sap polypeptide for use in the treatment of autoimmune disorders and graft vs host disease
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
EP2987803B1 (en) * 2009-06-17 2018-08-29 Promedior Inc. Sap variants and their use
ES2690542T3 (es) 2010-02-04 2018-11-21 Biomarin Pharmaceutical Inc. Método para purificar variantes de fenilalanina amoníaco-liasa procariotas
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
EP2877584A4 (en) * 2012-07-26 2016-03-30 Casa Luker S A METHODS FOR INCREASING THE PRODUCTION OF PHENOLIC COMPOUNDS FROM THEBROMA COCOA
NZ713396A (en) 2013-04-18 2020-06-26 Codexis Inc Engineered phenylalanine ammonia lyase polypeptides
WO2015161019A1 (en) 2014-04-16 2015-10-22 Codexis, Inc. Engineered tyrosine ammonia lyase
ES2881384T3 (es) 2015-05-13 2021-11-29 Synlogic Operating Co Inc Bacterias manipuladas para reducir la hiperfenilalaninemia
CN111655841A (zh) 2017-06-21 2020-09-11 同生运营公司 用于治疗紊乱的细菌
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US10900055B2 (en) 2018-06-12 2021-01-26 Codexis, Inc. Engineered tyrosine ammonia lyase
JP2021531749A (ja) * 2018-07-12 2021-11-25 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド
CA3122524A1 (en) 2018-12-14 2020-06-18 Codexis, Inc. Engineered tyrosine ammonia lyase
CN114828863A (zh) * 2019-10-17 2022-07-29 医肯纳肿瘤学公司 聚乙二醇化犬尿氨酸酶以及其用于治疗癌症的用途
JP2023512683A (ja) 2020-02-04 2023-03-28 コデクシス， インコーポレイテッド 操作されたロイシンデカルボキシラーゼ
BR112022018571A2 (pt) * 2020-03-20 2022-11-01 Synlogic Operating Co Inc Microrganismos manipulados para reduzir a hiperfenilalaninemia
CN116897205A (zh) 2020-08-28 2023-10-17 科德克希思公司 工程化淀粉酶变体
AU2021334371A1 (en) 2020-08-28 2023-03-09 Codexis, Inc. Engineered protease variants
JP2024540358A (ja) 2021-11-01 2024-10-31 シンティス バイオ，インコーポレイティド 工学操作ロイシン脱炭酸酵素
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
WO2025072636A1 (en) * 2023-09-28 2025-04-03 Aperiam Bio, Inc. Degradation of toxin in vivo

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
DK75593D0 (https=) * 1993-06-25 1993-06-25 Novo Nordisk As
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
US6395299B1 (en) 1999-02-12 2002-05-28 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2001257032A1 (en) 2000-04-14 2001-10-30 University Of South Carolina Research Foundation Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
US6967097B2 (en) * 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
KR20040088538A (ko) * 2002-02-26 2004-10-16 이 아이 듀폰 디 네모아 앤드 캄파니 유전 인자의 재조합 방법
JP2006516095A (ja) 2002-11-14 2006-06-22 ザ スクリップス リサーチ インスティテュート 脂肪酸アミドヒドロラーゼ（ｆａａｈ）の結晶形

Also Published As

Publication number Publication date
WO2006034373A9 (en) 2006-05-11
EP1814984A2 (en) 2007-08-08
US7553653B2 (en) 2009-06-30
WO2006034373A2 (en) 2006-03-30
AU2005286763A1 (en) 2006-03-30
JP2008513027A (ja) 2008-05-01
WO2006034373A8 (en) 2006-08-10
US20070048855A1 (en) 2007-03-01
WO2006034373A3 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
CA2580679A1 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
US6546074B1 (en) Protein crystal structure and method for identifying protein modulators
WO2001083769A2 (en) Crystallization of 4-diphosphocytidyl-2-c-methylerythritol synthesis
EP1409660A2 (en) Crystal structure of beta-site app cleaving enzyme (bace) and use thereof
AU6960696A (en) Crystalline zap family proteins
WO2001085748A2 (en) Designing modulators for glycosyltransferases
EP2665813A2 (en) Crystal structure of a type ib p-type atpase
French et al. Structural and kinetic insights into the mechanism of 5-hydroxyisourate hydrolase from Klebsiella pneumoniae
CA2615753A1 (en) Crystal structure of human soluble adenylate cyclase
WO2009076621A1 (en) High resolution structures of acidic mammalian chitinases and uses thereof
AU2007204226B2 (en) ACE N-domain crystal
WO2012037150A1 (en) Crystal structures of o-glcnac transferase and uses thereof
US20040157309A1 (en) Crystalline form of the catalytic domain of ADAM33 and methods of use thereof
WO2008142366A2 (en) Methods for selecting or designing modulators, based on the crystal structure of leukotriene c4 synthase (ltc4s)
CN1993379A (zh) 抗il－13抗体、抗il－13抗体的晶体以及包含它们的复合物
CA2349410A1 (en) Crystallized form of fc epsilon receptor alpha chain, its 3-d model and uses thereof
WO2009141455A1 (en) Immunogenic polypeptides that mimic the surface polysaccharide o-antigen from serotype 2a shigella flexneri, method for obtaining the same, and their use in vaccine and diagnostic compositions
GB2373504A (en) AMP deaminase crystal structure
CA2454572A1 (en) Crystalline pde4d2 catalytic domain complex, and methods for making and employing same
WO2004078910A2 (en) Identifying inhibitors of type ii isopentenyl diphosphate: dimethylallyl diphosphate isomerase
WO2004029236A1 (en) Atomic structure of the catalytic domain for use in designing and identifying inhibitors of zap-70 kinase
CA2982386A1 (en) Crystal structure of staphylococcus aureus autolysin e, method of producing the crystal and its use in screening methods
MXPA05012919A (en) CRYSTALLOGRAPHIC STRUCTURE OF TcPRACA AND USES THEREFOR
HK1120557A (en) Crystal structure of human soluble adenylate cyclase
AU5660900A (en) Crystalline zap family proteins

Legal Events

Date Code Title Description
FZDE Discontinued